Skip to content

CVCT CardioBrief

  • Home
  • About
    • Mission
  • CVCT Forum
  • Cardiobrief Archive
  • FAQ
    • Contact
    • Privacy Policy
    • Cookies Policy
    • Terms of use
  • Contact
  • Privacy Policy
  • Cookies Policy
  • Terms of use
search
  • Contact
  • Privacy Policy
  • Cookies Policy
  • Terms of use
search

Login / Signup

July 02, 2021

Thoughts about the use of the Win Ratio in Cardiovascular Outcome Trials

By :

Cardiovascular trials often include non-fatal events (in addition to mortality) in their primary endpoints maintain the study power i.e., to capture enough events to detect…

May 26, 20212021-05-26T06:58:17-04:00

Speculations on PARADISE-MI (sacubitril/valsartan post-MI) before the full results

By : Alexandra Nowbar

Marc Pfeffer presented the results of PARADISE-MI at ACC last week. As discussed previously on CVCTCardiobrief, sacubitril/valsartan did not reduce the primary outcome compared to…

May 16, 2021

Meet Spironolactone and Eplerenone’s Cardio-kidney Cousin, Finerenone

By : Alexandra Nowbar

Spironolactone and eplerenone improve outcomes in heart failure. Finerenone is the newest mineralocorticoid receptor antagonist and is being tested for treatment of chronic kidney disease…

May 11, 20212021-05-16T15:04:47-04:00

Preliminary Musings on PARADISE-MI (sacubitril-valsartan post MI)

By : Alexandra Nowbar

Cardiologists have been happily prescribing angiotensin receptor neprilysin inhibitor, sacubitril-valsartan, for heart failure with reduced ejection (HFrEF) for a while now. And the drug was…

April 05, 20212021-04-05T04:03:04-04:00

“Breakthrough” devices – to fast-track or not to fast-track

By : Alexandra Nowbar

In the US, the FDA (Food and Drug Administration) approves new medical devices. The CMS (Centers for Medicare & Medicaid Services) decides whether to cover…

February 12, 2021

The First Truly Effective Weight Loss Drug Arrives

By : Alexandra Nowbar

It looks like the first truly effective weight loss drug has arrived. Learn the basic facts about semaglutide and get perspectives from Milton Packer and Sanjay Kaul on what lies ahead.

February 06, 20212021-02-04T17:15:19-05:00

Trials in Heart Failure with Preserved Ejection Fraction: An Interview with Steve Nissen and Milton Packer

By : Alexandra Nowbar

Faiez Zannad moderates a fascinating discussion between Milton Packer and Steve Nissen about the PARAGON-HF trial in heart failure with preserved ejection fraction. Nissen was…

February 05, 20212021-02-04T17:12:25-05:00

Outtake from the Steve Nissen and Milton Packer discussion about PARAGON and TOPCAT moderated by Faiez Zannad

By : Alexandra Nowbar
February 05, 20212021-02-04T17:13:00-05:00

A Brand New Drug for Heart Failure with Reduced Ejection Fraction: An Interview with Javed Butler about Vericiguat

By : Alexandra Nowbar

Faiez Zannad speaks to Javed Butler about the FDA approval of new drug, vericiguat, for heart failure with reduced ejection fraction, following the publication of…

February 04, 2021

Global Trials Summit 2021: An Interview with John McMurray

By : Alexandra Nowbar

Faiez Zannad speaks to John McMurray about the Global Trials Summit being held virtually on 12th and 13th February 2021. Register here : https://global-trials-summit.hubilo.com/

Posts navigation

1 2 3 Next

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 296 other subscribers

  • Contact
  • Privacy Policy
  • Cookies Policy
  • Terms of use
  • Contact
  • Privacy Policy
  • Cookies Policy
  • Terms of use
 

Loading Comments...
 

You must be logged in to post a comment.